Education & Training Services
Compare Stocks
5 / 10Stock Comparison
UTI vs LPSN vs PRDO vs COCO vs GHC
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Application
Education & Training Services
Beverages - Non-Alcoholic
Education & Training Services
UTI vs LPSN vs PRDO vs COCO vs GHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Education & Training Services | Software - Application | Education & Training Services | Beverages - Non-Alcoholic | Education & Training Services |
| Market Cap | $1.96B | $32M | $2.16B | $3.90B | $4.90B |
| Revenue (TTM) | $869M | $244M | $855M | $659M | $3.75B |
| Net Income (TTM) | $43M | $-67M | $170M | $83M | $298M |
| Gross Margin | 24.0% | 62.2% | 51.8% | 37.2% | 27.7% |
| Operating Margin | 6.3% | -9.6% | 24.3% | 14.7% | 7.1% |
| Forward P/E | 44.5x | — | 12.0x | 41.1x | 17.0x |
| Total Debt | $279M | $392M | $105M | $13M | $1.73B |
| Cash & Equiv. | $127M | $95M | $132M | $197M | $267M |
UTI vs LPSN vs PRDO vs COCO vs GHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Universal Technical… (UTI) | 100 | 504.8 | +404.8% |
| LivePerson, Inc. (LPSN) | 100 | 0.3 | -99.7% |
| Perdoceo Education … (PRDO) | 100 | 324.3 | +224.3% |
| The Vita Coco Compa… (COCO) | 100 | 505.2 | +405.2% |
| Graham Holdings Com… (GHC) | 100 | 192.5 | +92.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UTI vs LPSN vs PRDO vs COCO vs GHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
UTI ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 14.0%, EPS growth 50.7%, 3Y rev CAGR 25.9%
- 9.7% 10Y total return vs PRDO's 5.1%
- PEG 0.53 vs GHC's 6.26
LPSN lags the leaders in this set but could rank higher in a more targeted comparison.
PRDO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 5 yrs, beta 0.48, yield 1.6%
- Lower volatility, beta 0.48, Low D/E 10.8%, current ratio 5.06x
- Beta 0.48, yield 1.6%, current ratio 5.06x
- 24.2% revenue growth vs LPSN's -22.0%
COCO is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +92.1% vs LPSN's -77.1%
- 18.1% ROA vs LPSN's -12.4%, ROIC 51.2% vs -6.6%
Among these 5 stocks, GHC doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 24.2% revenue growth vs LPSN's -22.0% | |
| Value | Lower P/E (12.0x vs 17.0x), PEG 1.77 vs 6.26 | |
| Quality / Margins | 19.9% margin vs LPSN's -27.6% | |
| Stability / Safety | Beta 0.48 vs LPSN's 2.05 | |
| Dividends | 1.6% yield, 5-year raise streak, vs GHC's 0.6%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +92.1% vs LPSN's -77.1% | |
| Efficiency (ROA) | 18.1% ROA vs LPSN's -12.4%, ROIC 51.2% vs -6.6% |
UTI vs LPSN vs PRDO vs COCO vs GHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
UTI vs LPSN vs PRDO vs COCO vs GHC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PRDO leads in 2 of 6 categories
COCO leads 1 • UTI leads 1 • LPSN leads 0 • GHC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
PRDO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GHC is the larger business by revenue, generating $3.7B annually — 15.4x LPSN's $244M. PRDO is the more profitable business, keeping 19.9% of every revenue dollar as net income compared to LPSN's -27.6%. On growth, COCO holds the edge at +37.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $869M | $244M | $855M | $659M | $3.7B |
| EBITDAEarnings before interest/tax | $78M | -$562,000 | $247M | $98M | $394M |
| Net IncomeAfter-tax profit | $43M | -$67M | $170M | $83M | $298M |
| Free Cash FlowCash after capex | $2M | -$43M | $221M | $65M | $286M |
| Gross MarginGross profit ÷ Revenue | +24.0% | +62.2% | +51.8% | +37.2% | +27.7% |
| Operating MarginEBIT ÷ Revenue | +6.3% | -9.6% | +24.3% | +14.7% | +7.1% |
| Net MarginNet income ÷ Revenue | +4.9% | -27.6% | +19.9% | +12.6% | +7.9% |
| FCF MarginFCF ÷ Revenue | +0.2% | -17.4% | +25.8% | +9.9% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.7% | -19.0% | +4.1% | +37.3% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -95.2% | +79.4% | +30.8% | +61.3% | +805.7% |
Valuation Metrics
PRDO leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 14.2x trailing earnings, PRDO trades at a 75% valuation discount to COCO's 57.3x P/E. Adjusting for growth (PEG ratio), UTI offers better value at 0.37x vs GHC's 6.24x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.0B | $32M | $2.2B | $3.9B | $4.9B |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $329M | $2.1B | $3.7B | $6.4B |
| Trailing P/EPrice ÷ TTM EPS | 31.45x | -0.22x | 14.23x | 57.32x | 16.96x |
| Forward P/EPrice ÷ next-FY EPS est. | 44.50x | — | 12.04x | 41.11x | 17.02x |
| PEG RatioP/E ÷ EPS growth rate | 0.37x | — | 2.09x | 3.80x | 6.24x |
| EV / EBITDAEnterprise value multiple | 15.02x | — | 8.97x | 44.32x | 15.03x |
| Price / SalesMarket cap ÷ Revenue | 2.34x | 0.13x | 2.55x | 6.39x | 1.00x |
| Price / BookPrice ÷ Book value/share | 6.02x | — | 2.34x | 12.34x | 1.01x |
| Price / FCFMarket cap ÷ FCF | 35.33x | — | 9.97x | 99.82x | 18.32x |
Profitability & Efficiency
COCO leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
COCO delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $6 for GHC. COCO carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to UTI's 0.85x. On the Piotroski fundamental quality scale (0–9), UTI scores 7/9 vs COCO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.0% | — | +17.2% | +25.4% | +6.4% |
| ROA (TTM)Return on assets | +5.2% | -12.4% | +13.2% | +18.1% | +3.7% |
| ROICReturn on invested capital | +14.3% | -6.6% | +15.3% | +51.2% | +3.3% |
| ROCEReturn on capital employed | +14.7% | -5.8% | +17.5% | +27.4% | +3.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 7 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.85x | — | 0.11x | 0.04x | 0.36x |
| Net DebtTotal debt minus cash | $152M | $297M | -$27M | -$184M | $1.5B |
| Cash & Equiv.Liquid assets | $127M | $95M | $132M | $197M | $267M |
| Total DebtShort + long-term debt | $279M | $392M | $105M | $13M | $1.7B |
| Interest CoverageEBIT ÷ Interest expense | 166.10x | 0.20x | 50.21x | — | 10.06x |
Total Returns (Dividends Reinvested)
UTI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in UTI five years ago would be worth $61,594 today (with dividends reinvested), compared to $35 for LPSN. Over the past 12 months, COCO leads with a +92.1% total return vs LPSN's -77.1%. The 3-year compound annual growth rate (CAGR) favors UTI at 79.7% vs LPSN's -65.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +43.1% | -31.1% | +18.9% | +27.6% | +4.0% |
| 1-Year ReturnPast 12 months | +20.0% | -77.1% | +15.4% | +92.1% | +17.7% |
| 3-Year ReturnCumulative with dividends | +480.7% | -95.8% | +195.8% | +193.3% | +98.4% |
| 5-Year ReturnCumulative with dividends | +515.9% | -99.7% | +198.5% | +404.5% | +76.3% |
| 10-Year ReturnCumulative with dividends | +973.7% | -97.0% | +505.6% | +404.5% | +147.0% |
| CAGR (3Y)Annualised 3-year return | +79.7% | -65.4% | +43.5% | +43.1% | +25.7% |
Risk & Volatility
Evenly matched — PRDO and COCO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRDO is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than LPSN's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. COCO currently trades 98.0% from its 52-week high vs LPSN's 12.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.89x | 2.05x | 0.48x | 0.65x | 0.87x |
| 52-Week HighHighest price in past year | $40.41 | $21.60 | $38.50 | $69.58 | $1224.76 |
| 52-Week LowLowest price in past year | $21.29 | $2.37 | $26.66 | $30.54 | $882.21 |
| % of 52W HighCurrent price vs 52-week peak | +87.9% | +12.4% | +89.5% | +98.0% | +92.1% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 40.3 | 46.2 | 77.7 | 50.8 |
| Avg Volume (50D)Average daily shares traded | 603K | 148K | 584K | 1.4M | 19K |
Analyst Outlook
Evenly matched — PRDO and GHC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: UTI as "Buy", PRDO as "Hold", COCO as "Buy". Consensus price targets imply 37.9% upside for UTI (target: $49) vs -12.9% for PRDO (target: $30). For income investors, PRDO offers the higher dividend yield at 1.62% vs GHC's 0.64%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Hold | Buy | — |
| Price TargetConsensus 12-month target | $49.00 | — | $30.00 | $67.86 | — |
| # AnalystsCovering analysts | 11 | — | 9 | 14 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.6% | — | +0.6% |
| Dividend StreakConsecutive years of raises | 0 | — | 5 | — | 9 |
| Dividend / ShareAnnual DPS | — | — | $0.56 | — | $7.17 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +5.6% | +0.3% | +0.1% |
PRDO leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). COCO leads in 1 (Profitability & Efficiency). 2 tied.
UTI vs LPSN vs PRDO vs COCO vs GHC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is UTI or LPSN or PRDO or COCO or GHC a better buy right now?
For growth investors, Perdoceo Education Corporation (PRDO) is the stronger pick with 24.
2% revenue growth year-over-year, versus -22. 0% for LivePerson, Inc. (LPSN). Perdoceo Education Corporation (PRDO) offers the better valuation at 14. 2x trailing P/E (12. 0x forward), making it the more compelling value choice. Analysts rate Universal Technical Institute, Inc. (UTI) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UTI or LPSN or PRDO or COCO or GHC?
On trailing P/E, Perdoceo Education Corporation (PRDO) is the cheapest at 14.
2x versus The Vita Coco Company, Inc. at 57. 3x. On forward P/E, Perdoceo Education Corporation is actually cheaper at 12. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Universal Technical Institute, Inc. wins at 0. 53x versus Graham Holdings Company's 6. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — UTI or LPSN or PRDO or COCO or GHC?
Over the past 5 years, Universal Technical Institute, Inc.
(UTI) delivered a total return of +515. 9%, compared to -99. 7% for LivePerson, Inc. (LPSN). Over 10 years, the gap is even starker: UTI returned +973. 7% versus LPSN's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UTI or LPSN or PRDO or COCO or GHC?
By beta (market sensitivity over 5 years), Perdoceo Education Corporation (PRDO) is the lower-risk stock at 0.
48β versus LivePerson, Inc. 's 2. 05β — meaning LPSN is approximately 323% more volatile than PRDO relative to the S&P 500. On balance sheet safety, The Vita Coco Company, Inc. (COCO) carries a lower debt/equity ratio of 4% versus 85% for Universal Technical Institute, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — UTI or LPSN or PRDO or COCO or GHC?
By revenue growth (latest reported year), Perdoceo Education Corporation (PRDO) is pulling ahead at 24.
2% versus -22. 0% for LivePerson, Inc. (LPSN). On earnings-per-share growth, the picture is similar: Universal Technical Institute, Inc. grew EPS 50. 7% year-over-year, compared to -59. 3% for Graham Holdings Company. Over a 3-year CAGR, UTI leads at 25. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — UTI or LPSN or PRDO or COCO or GHC?
Perdoceo Education Corporation (PRDO) is the more profitable company, earning 18.
9% net margin versus -27. 6% for LivePerson, Inc. — meaning it keeps 18. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRDO leads at 23. 2% versus -9. 6% for LPSN. At the gross margin level — before operating expenses — PRDO leads at 71. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is UTI or LPSN or PRDO or COCO or GHC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Universal Technical Institute, Inc. (UTI) is the more undervalued stock at a PEG of 0. 53x versus Graham Holdings Company's 6. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perdoceo Education Corporation (PRDO) trades at 12. 0x forward P/E versus 44. 5x for Universal Technical Institute, Inc. — 32. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for UTI: 37. 9% to $49. 00.
08Which pays a better dividend — UTI or LPSN or PRDO or COCO or GHC?
In this comparison, PRDO (1.
6% yield), GHC (0. 6% yield) pay a dividend. UTI, LPSN, COCO do not pay a meaningful dividend and should not be held primarily for income.
09Is UTI or LPSN or PRDO or COCO or GHC better for a retirement portfolio?
For long-horizon retirement investors, Perdoceo Education Corporation (PRDO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
48), 1. 6% yield, +505. 6% 10Y return). LivePerson, Inc. (LPSN) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRDO: +505. 6%, LPSN: -97. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between UTI and LPSN and PRDO and COCO and GHC?
These companies operate in different sectors (UTI (Consumer Defensive) and LPSN (Technology) and PRDO (Consumer Defensive) and COCO (Consumer Defensive) and GHC (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: UTI is a small-cap quality compounder stock; LPSN is a small-cap quality compounder stock; PRDO is a small-cap high-growth stock; COCO is a small-cap high-growth stock; GHC is a small-cap deep-value stock. PRDO, GHC pay a dividend while UTI, LPSN, COCO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.